rbd003

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
  2. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer
  3. Molecular biomarkers in localized prostate cancer: ASCO guideline
  4. Prognostic value of the SPOP mutant genomic subclass in prostate cancer
  5. Association of Presalvage Radiotherapy PSA Levels after Prostatectomy with Outcomes of Long-Term Antiandrogen Therapy in Men with Prostate Cancer
  6. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer
  7. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis
  8. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
  9. Feasibility and Impact of Emotional Intelligence Evaluation in Radiation Oncology Residency Interviews
  10. Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2
  11. A Pilot Study of Radiation Therapy in Combination with Pembrolizumab in Patients with Metastatic Renal Cell Cancer
  12. Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer: A Narrative Review of Mortality and Quality-of-Life Outcomes
  13. Overemphasis of Step 1 Scores May Affect Application Pool Diversity in Radiation Oncology
  14. Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions
  15. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice
  16. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier
  17. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer
  18. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma
  19. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
  20. Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions